Differentiation, Maintenance, and Analysis of Human Retinal Pigment Epithelium Cells: A Disease-in-a-dish Model for BEST1 Mutations
August 24th, 2018
6.2K views
Here we present a protocol to differentiate retinal pigment epithelium (RPE) cells from human pluripotent stem cells bearing patient-derived mutations. The mutant cell lines may be used for functional analyses including immunoblotting, immunofluorescence, and patch clamp. This disease-in-a-dish approach circumvents the difficulty of obtaining native human RPE cells.
Overview
This protocol describes the differentiation of retinal pigment epithelium (RPE) cells from human pluripotent stem cells with patient-derived mutations. This approach allows for functional analyses and addresses the challenges of obtaining native human RPE cells.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Stem Cell Research
Background
- Retinal pigment epithelium (RPE) cells are crucial for retinal health.
- Bestrophinopathies are a group of retinal diseases linked to BEST1 mutations.
- Obtaining native RPE cells from humans is challenging.
- Using patient-derived stem cells can provide insights into disease mechanisms.
Purpose of Study
- To develop a reliable method for differentiating RPE cells from human pluripotent stem cells.
- To facilitate research on BEST1 mutations and bestrophinopathies.
- To explore potential therapeutic applications for retinal diseases.
Methods Used
- Culture human pluripotent stem cells until confluency.
- Replace culture medium with differentiation medium.
- Supplement medium with human activin-A after two weeks.
- Continue culture until pigmented RPE cell clusters appear.
Main Results
- Successful differentiation of RPE cells from stem cells.
- Characterization of RPE cells for functional studies.
- Potential for use in cell replacement therapies.
- Insights into the pathology of bestrophinopathies.
Conclusions
- This method provides a valuable tool for studying retinal diseases.
- It offers a model for understanding BEST1 mutations.
- The approach may lead to advancements in therapeutic strategies.
Frequently Asked Questions
What are bestrophinopathies?
Bestrophinopathies are retinal diseases caused by mutations in the BEST1 gene, affecting retinal pigment epithelium function.
Why is it difficult to obtain native RPE cells?
Obtaining native RPE cells from human donors is challenging due to ethical and logistical issues.
How does this method benefit research?
It allows researchers to study disease mechanisms in a controlled environment using patient-derived cells.
What is the role of activin-A in this protocol?
Activin-A is used to promote the differentiation of stem cells into RPE cells during the culture process.
Can these RPE cells be used for therapies?
Yes, the differentiated RPE cells can potentially be used for cell replacement therapies in retinal diseases.
What functional analyses can be performed with these cells?
Functional analyses may include immunoblotting, immunofluorescence, and patch clamp studies.
Executive Industry Relevance
Human pluripotent stem cell-derived RPE models enable mechanistic interrogation of BEST1 mutations implicated in retinal degenerative diseases, overcoming the scarcity of native human RPE tissue. This disease-in-a-dish system supports predictive confidence in target validation and functional de-risking for early-stage ophthalmic drug discovery. The approach provides a renewable, patient-specific platform for portfolio triage and translational research continuity.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct functional analysis of BEST1 mutations in a human RPE context.
- Supports mechanistic de-risking by clarifying ion channel dysfunction and protein trafficking defects.
- Facilitates hypothesis-driven exploration of genotype-phenotype relationships in bestrophinopathies.
- Provides a renewable source of disease-relevant cells for iterative target validation.
Screening & Assay Development
- Generates standardized, mutation-specific RPE monolayers for quantitative patch clamp and imaging assays.
- Enables reproducible immunoblotting and immunofluorescence analyses across experimental runs.
- Supports assay scalability and platform reuse for compound screening targeting BEST1 function.
- Delivers robust, quantitative outputs for comparative evaluation of therapeutic candidates.
Translational & Preclinical Research
- Aligns in vitro disease models with patient-specific genetic backgrounds for translational biomarker discovery.
- Maintains continuity from early discovery through preclinical validation of RPE-targeted interventions.
- Enables risk-adjusted advancement decisions based on functional rescue or modulation of disease phenotypes.
- Supports mechanistic studies of ion transport relevant to clinical endpoints in retinal disease.
Pipeline & Workflow Integration
This hPSC-RPE differentiation and analysis workflow bridges early discovery, lead identification, and preclinical research for BEST1-associated retinal diseases.
- Discovery Biology: Provides a platform for null hypothesis testing of BEST1 mutation effects on RPE physiology.
- Screening: Delivers standardized, quantitative readouts for functional screening of candidate therapeutics.
- Analytics: Enables measurement of protein expression, membrane trafficking, and ion channel activity for comparative analysis.
- Translational Research: Facilitates alignment of in vitro findings with patient-derived disease mechanisms.
- Enterprise Reuse: Offers a scalable, renewable system adaptable to other RPE-expressed genes and mutations.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and mechanistic understanding of BEST1 pathology.
- Operational Value: Standardizes RPE cell production and analysis for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk in ophthalmic portfolios.
- Portfolio Impact: Enables risk-adjusted prioritization of therapeutic programs targeting retinal degenerative diseases.
Implementation Considerations
- Requires expertise in hPSC culture, differentiation, and RPE-specific analytical techniques.
- Demands access to cell culture, imaging, and electrophysiology instrumentation.
- Necessitates cross-team standardization of differentiation and assay protocols for reproducibility.
- Adaptation may be needed for different hPSC lines or mutation types, affecting timelines.
- Cell viability and maturation rates can vary, requiring careful optimization and quality control.
Biopharma FAQs
Why does null hypothesis testing of BEST1-RPE function matter?
Null hypothesis testing using hPSC-derived RPE cells enables rigorous evaluation of whether specific BEST1 mutations alter protein expression, trafficking, or ion channel activity, supporting confident target validation and mechanistic de-risking in early discovery.
How does independent variable isolation in RPE differentiation fit the discovery pipeline?
Isolating the effects of individual BEST1 mutations in a controlled hPSC-RPE system allows teams to attribute observed phenotypes directly to genetic changes, streamlining mechanistic studies and informing downstream screening strategies.
What do quantitative patch clamp and protein assays enable in this workflow?
Quantitative patch clamp and protein analyses provide objective, reproducible measurements of ion channel function and protein localization, enabling comparative assessment of disease versus control RPE cells for therapeutic evaluation.
Why are replication requirements critical for cross-functional RPE studies?
Replication across multiple hPSC lines and differentiation batches ensures that observed BEST1-related phenotypes are robust and generalizable, facilitating cross-team data integration and portfolio-level decision making.
What statistical analysis capabilities are required before RPE model implementation?
Robust statistical analysis of functional and molecular readouts is essential to distinguish true mutation effects from background variability, supporting reliable interpretation and actionable insights for R&D advancement.
Chapters in this video
0:04
Title
0:41
Differentiation of Human Pluripotent Stem Cells (hPSC) to Retinal Pigment Epithelium (RPE) Cells and Isolation
3:02
Whole-cell Patch Clamp RPE Cell Culture Preparation
4:42
Results: Representative Mature RPE Cell Status Validation
5:28
Conclusion
